T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.58B |
| 2 |
T-Mobile US
TMUS
|
+$1.53B |
| 3 |
Morgan Stanley
MS
|
+$1.15B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.15B |
| 5 |
Apple
AAPL
|
+$1.14B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$2.94B |
| 2 |
Amazon
AMZN
|
+$2.82B |
| 3 |
GE Aerospace
GE
|
+$1.93B |
| 4 |
Goldman Sachs
GS
|
+$1.88B |
| 5 |
ServiceNow
NOW
|
+$1.28B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.25% |
| 2 | Healthcare | 17.75% |
| 3 | Financials | 11.32% |
| 4 | Consumer Discretionary | 11.17% |
| 5 | Communication Services | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Agios Pharmaceuticals
AGIO
$2B
| $29M | ﹤0.01% |
1,263,697
-216,497
| -15% | -$5.75M |
|
827
Monte Rosa Therapeutics
GLUE
$1.35B
| $28.8M | ﹤0.01% |
3,693,494
+10,064
| +0.3% | +$70K |
|
828
Element Solutions
ESI
$9.51B
| $28.7M | ﹤0.01% |
1,488,144
-2,723,941
| -65% | -$53.7M |
|
829
Allegiant Air
ALGT
$2.36B
| $28.6M | ﹤0.01% |
311,406
+8,603
| +3% | +$773K |
|
830
Clorox
CLX
$12.9B
| $28.6M | ﹤0.01% |
180,811
+7,226
| +4% | +$1.08M |
|
831
ATI
ATI
$30.9B
| $28.1M | ﹤0.01% |
712,994
+662,166
| +1,303% | +$25M |
|
|
ENV
832
DELISTED
ENVESTNET, INC.
ENV
| $28M | ﹤0.01% |
477,876
-15,563
| -3% | -$966K |
|
833
XPO
XPO
$24.7B
| $27.9M | ﹤0.01% |
874,667
+45,896
| +6% | +$1.65M |
|
834
Hewlett Packard
HPE
$79.2B
| $27.8M | ﹤0.01% |
1,743,273
+23,590
| +1% | +$371K |
|
|
BKI
835
DELISTED
Black Knight, Inc. Common Stock
BKI
| $27.8M | ﹤0.01% |
482,430
-4,706,855
| -91% | -$282M |
|
836
Concentrix
CNXC
$1.52B
| $27.7M | ﹤0.01% |
227,475
-77,251
| -25% | -$10.5M |
|
837
ICU Medical
ICUI
$4.58B
| $27.6M | ﹤0.01% |
167,112
-58,146
| -26% | -$10M |
|
|
PPL
838
PPL Corp
PPL
$26.8B
| $27.4M | ﹤0.01% |
987,383
+30,066
| +3% | +$851K |
|
839
Flowserve
FLS
$10.3B
| $27.4M | ﹤0.01% |
806,188
-147,180
| -15% | -$4.93M |
|
840
Evolent Health
EVH
$527M
| $27.4M | ﹤0.01% |
843,944
-3,185
| -0.4% | -$101K |
|
|
RETA
841
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $27M | ﹤0.01% |
297,065
+277,696
| +1,434% | +$16.3M |
|
842
Labcorp
LH
$26.2B
| $27M | ﹤0.01% |
136,917
-21,595
| -14% | -$4.44M |
|
|
DHR.PRB
843
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| – | – |
0
| – | – |
|
844
Skyward Specialty Insurance
SKWD
$2.39B
| $26.9M | ﹤0.01% |
+1,230,449
| New | +$23.9M |
|
845
FormFactor
FORM
$10.3B
| $26.9M | ﹤0.01% |
844,012
-142,970
| -14% | -$4.1M |
|
846
Tradeweb Markets
TW
$22.3B
| $26.7M | ﹤0.01% |
337,446
-28,594
| -8% | -$2.07M |
|
|
CVAC
847
DELISTED
CureVac
CVAC
| $26.6M | ﹤0.01% |
3,813,896
+3,260,031
| +589% | +$28.4M |
|
848
Nasdaq
NDAQ
$54.6B
| $26.2M | ﹤0.01% |
479,123
-95,044
| -17% | -$5.49M |
|
849
Lumentum
LITE
$78B
| $26.2M | ﹤0.01% |
484,398
-19,333
| -4% | -$1.08M |
|
850
Celldex Therapeutics
CLDX
$3.35B
| $25.7M | ﹤0.01% |
713,562
-119,447
| -14% | -$5.15M |
|
Similar funds
T. Rowe Price Associates's Q1 2023 Portfolio in Review
As of Q1 2023, T. Rowe Price Associates held 3,020 positions worth $668B, up 7.5% from $622B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2023 filing shows 65 new, 1,711 increased, 924 reduced and 98 closed positions. Its largest new stake was Suncor Energy: 6,437,236 shares worth $200M. The largest sale was Alphabet (Google) Class C, an estimated $2.94B.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2023 buy was Suncor Energy: 6,437,236 shares worth $200M.
- T. Rowe Price Associates added most to Tesla in Q1 2023, an estimated $1.58B increase.
- T. Rowe Price Associates's biggest Q1 2023 reduction was Alphabet (Google) Class C, cutting an estimated $2.94B.
- T. Rowe Price Associates fully exited Signature Bank in Q1 2023, selling an estimated $360M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $668B portfolio in Q1 2023.
- T. Rowe Price Associates opened 65 new positions and closed 98 in Q1 2023.
- T. Rowe Price Associates's portfolio value rose 7.5% quarter-over-quarter to $668B.
Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.